Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients

Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD). Recently, a retrospective study showed that the effect of tolvaptan on kidney function could be sustained for a long period....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Nephrol Dial
Main Authors: Nakatani, Shinya, Ishimura, Eiji, Machiba, Yuri, Fujimoto, Kenta, Uedono, Hideki, Tsuda, Akihiro, Mori, Katsuhito, Emoto, Masanori, Inaba, Masaaki
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098338/
https://ncbi.nlm.nih.gov/pubmed/32232055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000506118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados